A phase I study to assess the safety, tolerability, pharmacokinetic profile and pharmacodynamic effect of single and multiple doses of VAK694 in healthy and atopic subjects
Latest Information Update: 26 Mar 2008
At a glance
- Drugs VAK 694 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis
- 26 Mar 2008 New trial record.